REGNRegeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc.17,590
Mkt Cap
$77.47BVolume
177.0052W High
$821.1152W Low
$476.49PE Ratio
17.63REGN Fundamentals
Price
$732.87Prev Close
$737.45Open
$738.1750D MA
$766.57Beta
0.63Avg. Volume
751,970.32EPS (Annual)
$41.48P/B
2.48Rev/Employee
$930,752.76$78,186.98
Union Bancaire Privee UBP SA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Union Bancaire Privee UBP SA lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 672.3% in the fourth quarter, according to the company in its most recent...
MarketBeat·2d ago
CIBC Bancorp USA Inc. Makes New $10.13 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
CIBC Bancorp USA Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 18,022 shares of the biopharmaceut...
MarketBeat·2d ago
Futures Slide Ahead Of Massive $5.7 Trillion OpEx As Iran War Shows No Signs Of Easing
Futures Slide Ahead Of Massive $5.7 Trillion OpEx As Iran War Shows No Signs Of Easing Futures are weaker heading into the weekend after US equities finished lower yesterday despite Netanyahu...
Zero Hedge·3d ago
Regeneron Pharmaceuticals Takes Over #140 Spot From Emerson Electric
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) has taken over the #140 spot from Emerson Electric Co. (Symbol: EMR), according to The Online Investor.
Market capitali...
Nasdaq News: Markets·4d ago
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Zacks·4d ago
Hudson Bay Capital Management LP Sells 31,367 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Hudson Bay Capital Management LP cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 48.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,791 shares of the biopharmaceuti...
MarketBeat·4d ago
Groupama Asset Managment Sells 5,169 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Groupama Asset Managment lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,701 shares of the biopharmaceutical company...
MarketBeat·4d ago
Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement
(RTTNews) - Formycon AG (FYB.DE, FYBGF), an independent German biotechnology company, on Thursday announced that it entered into a settlement and license agreement with Regeneron Pharmaceuticals...
Nasdaq News: Markets·4d ago
BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD
Bayer's finerenone hits key phase III goal in non-diabetic CKD, paving the way to expand Kerendia???s use as data strengthens its cardiorenal therapy role.
Zacks·6d ago
Holocene Advisors LP Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN
Holocene Advisors LP acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·6d ago
<
1
2
...
>